Apogee Therapeutics
APGE
85 hedge funds and large institutions have $1.17B invested in Apogee Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 9 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 9
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
37% more capital invested
Capital invested by funds: $849M → $1.17B (+$317M)
16% more funds holding
Funds holding: 73 → 85 (+12)
4.64% more ownership
Funds ownership: 107.85% → 112.49% (+4.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$9.39M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.72M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$3.81M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$10.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.18M |
| 3 |
O
OrbiMed
New York
|
-$3.01M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$2.38M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.82M |
APGE Hedge Fund Activity: Q4 2023 in Review
85 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q4 2023, worth a combined $1.17B — up 37% from $849M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new APGE positions and 9 closed out — a net gain of 12 holders — while 33 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $11.6M. The largest seller was Affinity Asset Advisors, cutting an estimated $10.2M.
- 85 institutional investors held Apogee Therapeutics (APGE) as of Q4 2023, up from 73 in Q3 2023.
- Funds reported $1.17B of Apogee Therapeutics stock for Q4 2023, up 37% quarter-over-quarter.
- 21 funds opened new Apogee Therapeutics positions in Q4 2023 and 9 closed out, a net change of +12 holders.
- The largest Apogee Therapeutics buyer in Q4 2023 was Fidelity Investments, an estimated $11.6M added.
- The largest Apogee Therapeutics seller in Q4 2023 was Affinity Asset Advisors, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2023.